As experts in fluidtransferology, Beckman Coulter Life Sciences offers a broad range of flexible, scalable liquid handling solutions and reagents for NGS, genomic, cellular, protein and other workflows — including areas such as synthetic biology and more.
Use the Biomek i-Series to automate complex steps of the protocol. Transform and culture bacterial cells and prepare DNA samples for use with this liquid handler. Perform initial testing of your product, from transduction or analytical characterization, and scale therapeutic biological production downstream of this workflow.
The Echo 525 Acoustic Liquid Handler flexes across every step of a synthetic biology workflow while miniaturizing reactions and consuming less resources.
Our reagent portfolio is powered by Solid Phase Reversible Immobilization (SPRI) technology—widely known as the science behind AMPure XP—which uses SPRI paramagnetic beads to selectively bind nucleic acids by size.

Inscripta is a life science technology company enabling scientists to solve some of today’s most pressing challenges with the first benchtop system for genome editing. The company’s automated Onyx™ platform, consisting of an instrument, consumables, assays, and software, makes CRISPR-based genome engineering accessible to any research lab. Inscripta supports its customers around the world from facilities in Boulder, Colo.; San Diego and Pleasanton, Calif.; and Copenhagen, Denmark. To learn more, visit Inscripta.com and follow @InscriptaInc.

Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomic applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases.

Samplix supports the life sciences and medical research communities with proprietary microfluidics-based solutions designed to deliver the highest-resolution insights into cells and genomes. Our technology encapsulates single mammalian, bacterial or yeast cells, DNA, and other biological material together with assay chemistry. This supports a range of downstream analyses: functional analyses of single mammalian cells, assessments of single-cell enzyme activity, characterization of edits in engineered genes, and even cell incubation. As a leading developer of microfluidics solutions, Samplix stands ready to help researchers reach their goals in areas as diverse as gene and cell therapy, synthetic biology, and molecular engineering.

Syngulon is a synthetic biology startup developing original genetic technologies using bacteriocins to improve microbial fermentation.
Our team of scientists works in different academic laboratories and our R&D programs involve partners from Belgium, Brazil, France, Germany, The Netherlands, and the UK. We think of ourselves as a “Startup in the Labs”, meaning that we work directly in the labs of our academic partners.
The members of our Scientific Advisory Board are active in Belgium, France and the USA.

IBioIC is a networking and support organisation that connects industry, academia and government to bring biotechnology processes and products to the global market. We do this by offering scale-up facilities, talent development, funding provision, and promotion of Scotland’s unique assets.

We are leading the way in promoting excellence and equality in science, and in channelling high quality knowledge to solving today’s societal problems around microbiology. We do this by funding research, giving out travel and training grants to scientists, publishing our journals, running events, and managing collaborative projects with other partner organizations.